Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 17, 04 December 2023
Open
Access | Article
The vaccine of the type one diabetes
* Author to whom correspondence should be addressed.
Abstract
At present, the main patients of T1D (type one diabetes) are adolescents and many complications will occur, which is very harmful to the health of adolescents. This article mainly discusses the development and research progress of T1D vaccine. Current potential vaccines include antigen isolation vaccines, APL, monopeptide vaccines and adjuvant vaccines. Among them, autoantigen IA2-based antigen-specific vaccine Hsp65-6IA2P2 protein vaccine and B9-23 APL-based vaccine can effectively minimize the natural diabetes prevalence in NOD mice, DiaPep277 vaccine is based on heat shock protein 60 (Hsp60), which was displayed to maintain C peptide levels in phase I experiments, but phase II trials are not very successful, and are currently entering phase III experiments. The widely used adjuvant alum was combined with the adjuvant vaccine “Diamyd” by GAD65. Diamyd therapy has been successful in adults and has been carried out in phase II studies on kids and teens, with phase III trials currently underway in Europe and the United States.
Keywords
Type One Diabetes, Antigen Specific Vaccine, APL, Monopeptide Vaccines, Adjuvant Vaccines
References
1. Bresson, Damien, and Matthias von Herrath. 2004. ‘Mechanisms Underlying Type 1 Diabetes’. Drug Discovery Today: Disease Mechanisms 1 (3): 321–27.
2. ‘Type 1 Diabetes - Symptoms and Causes’. n.d. Mayo Clinic. Accessed 15 August 2023. https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/symptoms-causes/syc-20353011.
3. Gregory, Gabriel A., Thomas I. G. Robinson, Sarah E. Linklater, Fei Wang, Stephen Colagiuri, Carine de Beaufort, Kim C. Donaghue, et al. 2022. ‘Global Incidence, Prevalence, and Mortality of Type 1 Diabetes in 2021 with Projection to 2040: A Modelling Study’. The Lancet Diabetes & Endocrinology 10 (10): 741–60.
4. ‘Type 1 Diabetes: MedlinePlus Genetics’. n.d. Accessed 4 September 2023. https://medlineplus. gov/genetics/condition/type-1-diabetes/.
5. Lee, Hae Sang, and Jin Soon Hwang. 2019. ‘Genetic Aspects of Type 1 Diabetes’. Annals of Pediatric Endocrinology & Metabolism 24 (3): 143–48.
6. ‘Causes and Risk Factors | Background Information | Diabetes - Type 1 | CKS | NICE’. n.d. Accessed 4 September 2023. https://cks.nice.org.uk/topics/diabetes-type-1/background-information/causes-risk-factors/.
7. Masakazu Kobayashi, Norio Abiru, Takeshi Arakawa, Keiko Fukushima, Hongbo Zhou, Eiji Kawasaki, Hironori Yamasaki, Edwin Liu, Dongmei Miao, F. Susan Wong, George S. Eisenbarth, Katsumi Eguchi; Altered B:9–23 Insulin, When Administered Intranasally with Cholera Toxin Adjuvant, Suppresses the Expression of Insulin Autoantibodies and Prevents Diabetes1. J Immunol 15 August 2007; 179 (4): 2082–2088.
8. Nicholas, Dequina, Oludare Odumosu, and William H.R. Langridge. 2011. ‘Autoantigen Based Vaccines for Type 1 Diabetes’. Discovery Medicine 11 (59): 293–301.
9. Raz, Itamar, Dana Elias, Ann Avron, Merana Tamir, Muriel Metzger, and Irun R. Cohen. 2001. ‘β-Cell Function in New-Onset Type 1 Diabetes and Immunomodulation with a Heat-Shock Protein Peptide (DiaPep277): A Randomised, Double-Blind, Phase II Trial’. The Lancet 358 (9295): 1749–53.
10. Itamar Raz, Anette G. Ziegler et.al, The DIA-AID 1 Writing Group; Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. Diabetes Care 1 May 2014; 37 (5): 1392–1400.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-197-1
- ISBN (Online)
- 978-1-83558-198-8
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/17/20240642
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited